NEW YORK and SAN DIEGO, April 20, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and Cypress Bioscience, Inc. (Nasdaq: CYPB) announced today that Savella(TM) (milnacipran HCl), a selective serotonin and norepinephrine dual reuptake inhibitor approved for the management of fibromyalgia, will be shipped to wholesalers on April 24th and will be available at pharmacies beginning on April 28th. After Savella was approved by the U.S. Food and Drug Administration (FDA) on January 14, 2009, the companies submitted a minor post-approval cosmetic formulation change to the FDA which … [Read more...]
Fibromyalgia Presents a Real and Significant Market Opportunity
Pardon me while I step upon my soapbox again. Excuse me while I clear my throat and take a sip of water. Give me just one moment to arrange my notes and organize my thoughts. Now please, stand back if you do not want to feel any of the vile comments I am about to spew forth. Here goes. I HATE DRUG COMPANIES! I hate that their sole purpose is to profit off the needs and health concerns of the public. I hate that they view every illness as an opportunity to line their pockets. I hate that they perpetuate a culture of sickness by treating symptoms and not caring to find a cure. Why would they … [Read more...]